Overview

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
Phase:
Phase 3
Details
Lead Sponsor:
ACADIA Pharmaceuticals Inc.
Treatments:
Carbetocin